# Fervent Synergi (NSE: FERVENTSYN) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/FERVENTSYN · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹68 Cr, it ranks 2893rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Food Distribution.

Its return on equity was 6.1% in FY25. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹1 Cr (+8.8% year on year) and net profit ₹0 Cr (−47.4%), on a standalone basis. Promoters held 74.75% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹68 Cr |
| ROE | 6.1% (FY25) |
| ROCE | 6.1% (FY25) |
| Debt to equity | 0 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹1 Cr | +8.8% | ₹0 Cr | −47.4% | ₹0.04 |
| Q4 FY26 | ₹5 Cr | −3.7% | ₹1 Cr | +74.0% | ₹0.17 |
| Q3 FY26 | ₹10 Cr | −62.9% | ₹2 Cr | −8.9% | ₹0.43 |
| Q2 FY26 | ₹1 Cr | +74.4% | ₹0 Cr | +975.0% | ₹0.09 |
| Q1 FY26 | ₹1 Cr | +100.0% | ₹0 Cr | +442.9% | ₹0.08 |
| Q4 FY25 | ₹5 Cr | −63.6% | ₹1 Cr | — | ₹0.11 |
| Q3 FY25 | ₹26 Cr | +198.2% | ₹2 Cr | +535.1% | ₹0.54 |
| Q2 FY25 | ₹0 Cr | +21.9% | ₹0 Cr | −55.6% | ₹0.01 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹32 Cr | ₹3 Cr |
| FY24 | ₹24 Cr | −₹13 Cr |
| FY23 | ₹5 Cr | ₹0 Cr |
| FY22 | ₹1 Cr | −₹0 Cr |
| FY21 | ₹2 Cr | ₹0 Cr |
| FY20 | ₹7 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 74.75%
- Non-institutions: 25.25%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Maestros Elect](https://app.pivotnow.in/stock/METSL) | — | ₹76 Cr | — | — |
| [Bharat Immuno](https://app.pivotnow.in/stock/BIBCL) | — | ₹75 Cr | — | — |
| [Source Natural](https://app.pivotnow.in/stock/SOURCENTRL) | — | ₹70 Cr | — | — |
| [Asston Pharma](https://app.pivotnow.in/stock/APL) | — | ₹69 Cr | — | — |
| [Sunil Health](https://app.pivotnow.in/stock/SUNLOC) | ₹65.00 | ₹67 Cr | 16.6 | — |
| [Samrat Pharma](https://app.pivotnow.in/stock/SAMRATPH) | — | ₹61 Cr | — | — |

## Questions and answers

### What is the market cap of Fervent Synergi?

Fervent Synergi's market capitalisation is ₹68 Cr (₹68 Cr) at the 22 Oct 2026 close, ranking 2893rd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Fervent Synergi?

Return on equity was 6.1% in FY25 and return on capital employed was 6.1% in FY25 (standalone figures).

### Is Fervent Synergi a debt-free company?

Fervent Synergi is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were Fervent Synergi's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Fervent Synergi reported revenue of ₹1 Cr, +8.8% year on year, and net profit of ₹0 Cr, −47.4% year on year.

### What is the shareholding pattern of Fervent Synergi?

As of 30 Jun 2026: promoters 74.75%, non-institutions 25.25%.

### Who are Fervent Synergi's competitors?

The listed Pharma & Healthcare companies closest to Fervent Synergi by market cap are Maestros Elect, Bharat Immuno, Source Natural, Asston Pharma, Sunil Health and Samrat Pharma.

### Is Fervent Synergi a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Fervent Synergi's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FERVENTSYN against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.